Contact pemphigus: a side-effect of imiquimod therapy.
Lo Schiavo
Ada
A
Sangiuliano
Sonia
S
Puca
Rosa Valentina
RV
Brunetti
Giampiero
G
Ruocco
Eleonora
E
Cozzi
Roberto
R
D000287:Administration, Topical; D000634:Aminoquinolines / Q000009:adverse effects* / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001707:Biopsy, Needle; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D019085:Fluorescent Antibody Technique, Direct; D005500:Follow-Up Studies; D006801:Humans; D000077271:Imiquimod; D007150:Immunohistochemistry; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D027383:Papillomaviridae / Q000187:drug effects / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000188:drug therapy; D010392:Pemphigus / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology*; D011241:Prednisone / Q000627:therapeutic use; D018570:Risk Assessment; D016896:Treatment Outcome; D014845:Vulvar Diseases / Q000188:drug therapy / Q000821:virology
D000634:Aminoquinolines; D001379:Azathioprine; D000077271:Imiquimod; D011241:Prednisone; D008775:Methylprednisolone